[
  {
    "ts": null,
    "headline": "Is Bio-Techne (TECH) Fairly Priced After Recent Share Price Rebound?",
    "summary": "If you are wondering whether Bio-Techne at around US$65 per share offers good value today, you are not alone. This article focuses squarely on what that price might mean for long term investors. The stock has had a mixed recent run, with a 9.4% gain over the past month, a 9.4% return year to date, but a 1 year return of 8.9% decline and a 5 year return of 31.8% decline that may leave some holders questioning what comes next. Recent attention on Bio-Techne has been shaped by ongoing interest...",
    "url": "https://finnhub.io/api/news?id=6539e3618df5bae619a7a15e1d70cfc7eedd88a248016563f43ba9b3d7822bbe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770128139,
      "headline": "Is Bio-Techne (TECH) Fairly Priced After Recent Share Price Rebound?",
      "id": 138342980,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "If you are wondering whether Bio-Techne at around US$65 per share offers good value today, you are not alone. This article focuses squarely on what that price might mean for long term investors. The stock has had a mixed recent run, with a 9.4% gain over the past month, a 9.4% return year to date, but a 1 year return of 8.9% decline and a 5 year return of 31.8% decline that may leave some holders questioning what comes next. Recent attention on Bio-Techne has been shaped by ongoing interest...",
      "url": "https://finnhub.io/api/news?id=6539e3618df5bae619a7a15e1d70cfc7eedd88a248016563f43ba9b3d7822bbe"
    }
  },
  {
    "ts": null,
    "headline": "Bio-Techne (TECH) Reports Earnings Tomorrow: What To Expect",
    "summary": "Life sciences company Bio-Techne (NASDAQ:TECH) will be announcing earnings results this Wednesday before market open. Here’s what to look for.",
    "url": "https://finnhub.io/api/news?id=d31b64348153da32a269368985494572c728bcc1f4c0032aa26bf903c4141e2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770087883,
      "headline": "Bio-Techne (TECH) Reports Earnings Tomorrow: What To Expect",
      "id": 138338617,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Life sciences company Bio-Techne (NASDAQ:TECH) will be announcing earnings results this Wednesday before market open. Here’s what to look for.",
      "url": "https://finnhub.io/api/news?id=d31b64348153da32a269368985494572c728bcc1f4c0032aa26bf903c4141e2e"
    }
  },
  {
    "ts": null,
    "headline": "A Look At Bio Techne (TECH) Valuation After Cultrex Synthetic Hydrogel Launch",
    "summary": "Bio-Techne (TECH) shares are back in focus after the company introduced Cultrex Synthetic Hydrogel, a fully defined extracellular matrix designed to improve reproducibility, scalability, and regulatory alignment in 3D stem cell and organoid research. See our latest analysis for Bio-Techne. These product launches in organoid and neurology research have arrived during a period where the share price has a 30 day return of 9.39% and a year to date share price return of 9.39%, while the 1 year...",
    "url": "https://finnhub.io/api/news?id=7cc43c212b70a6f4eb39824f89c604c791d4483a21a1890a99c05892009e4a32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770084673,
      "headline": "A Look At Bio Techne (TECH) Valuation After Cultrex Synthetic Hydrogel Launch",
      "id": 138338618,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Bio-Techne (TECH) shares are back in focus after the company introduced Cultrex Synthetic Hydrogel, a fully defined extracellular matrix designed to improve reproducibility, scalability, and regulatory alignment in 3D stem cell and organoid research. See our latest analysis for Bio-Techne. These product launches in organoid and neurology research have arrived during a period where the share price has a 30 day return of 9.39% and a year to date share price return of 9.39%, while the 1 year...",
      "url": "https://finnhub.io/api/news?id=7cc43c212b70a6f4eb39824f89c604c791d4483a21a1890a99c05892009e4a32"
    }
  }
]